The development of effective immunotherapies, and particularly cell therapies, is the single most important pharmaceutical challenge for ALK+ NSCLC today, since no other systemic treatment, including TKI, has so far been able to eradicate these tumors. Here, ALK is linked to non-small cell lung carcinoma.